



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/526,028	Zhihui Liu	186326/US

25763

DORSEY & WHITNEY LLP

INTELLECTUAL PROPERTY DEPARTMENT

SUITE 1500

50 SOUTH SIXTH STREET

MINNEAPOLIS, MN 55402-1498

FEB 01 2007

INTERNATIONAL APPLICATION NO.

PCT/CN02/00660

I.A. FILING DATE

PRIORITY DATE

09/16/2002

08/28/2002

DOCKETED

RESPONSE DUE:

Mar 29, 2007 / Jul 29, 2007

CONFIRMATION NO. 4794

371 FORMALITIES LETTER



OC000000022209077

Date Mailed: 01/29/2007


NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 11 FR 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to pay an application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:



DISK TO STIC

DATE:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/526,028	PCT/CN02/00660	186326/US

FORM PCT/DO/EO/922 (371 Formalities Notice)



Docket: 186326/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


First Named Inventor:	Zhihui Liu	Confirmation No. 4794
Appln. No.:	10/526,028	Examiner: Unknown
Filed:	February 28, 2005	Group Art
Title:	THE SYNERGISTIC EFFECT OF OGP AND G-CSF ON HAEMATOGENESIS	Unit: 1614

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

MAIL STOP Missing Parts

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this document is being sent via First Class U.S. mail addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 29th day of March, 2007.


Susan Nienaber

Sir:


Pursuant to the requirements of § 1.821(e), I hereby state that in accordance with the requirements of § 1.824(d), a diskette containing a computer readable form of the Sequence Listing filed herewith. The material on this diskette is identical in substance to the Sequence Listing appearing on page 5 of the specification originally filed. No new matter has been added. The materials filed herewith is identical to the paper copy and electronic version of this Sequence Listing which was originally filed with the application on February 28, 2005.

As required in the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, a copy of the Notice is also enclosed.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

Date: March 29, 2007


BY: Sean D. Solberg, Reg. No. 48,653
(612) 340-7862